Sara A. Hurvitz, MD, FACP
Dr. Sara Hurvitz is an internationally recognized expert in oncology and a pioneer in the clinical development of ADCs and other targeted therapies for breast cancer. Additionally, as a leader in clinical and laboratory-based oncology research, she has led numerous global clinical trials spanning all phases of development and has been instrumental in advancing ADCs and immune-based treatments that have redefined standards of care in breast cancer.
Dr. Hurvitz currently serves as Professor of Medicine and Division Head of Hematology/Oncology at the University of Washington School of Medicine, and as the Senior Vice President of the Clinical Research Division at Fred Hutchinson Cancer Center. She previously directed the breast oncology program at the University of California, Los Angeles (UCLA), where she joined the faculty in 2006, and co-directed the Santa Monica-UCLA Outpatient Oncology Practice. She also formerly served as the medical director of the clinical research unit for UCLA’s Jonsson Comprehensive Cancer Center.
Over her distinguished career, Dr. Hurvitz has won numerous awards, among them the Marni Levine Memorial Breast Cancer Research Award 2008 through 2015 and the European Society of Medical Oncology Breast Cancer Award in 2023. She has an active clinical practice specializing in the treatment of women with breast cancer and continues to be involved in designing, implementing, and leading multiple national and international clinical trials testing new targeted therapies.
Dr. Hurvitz earned her MD from the University of Southern California. She served an internship/residency at UCLA, was Chief Resident of internal medicine, and completed a hematology-oncology fellowship at UCLA in 2006. Dr. Hurvitz received board certification in internal medicine, hematology, and medical oncology. She is a member of the American College of Physicians, the American Society of Hematology, the American Society of Clinical Oncology, American Association for Cancer Research and the European Society of Medical Oncology.
